Arch Oncology, Inc

4320 Forest Park Avenue
Suite 304
St. Louis
MO
63108
United States

Show jobs for this employer

About Arch Oncology, Inc

Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of cancer.  Anti-CD47 therapies represent a new class of checkpoint inhibitors that bridge the innate and adaptive immune systems to attack cancer. Arch Oncology has developed a functionally diverse antibody platform and is advancing a novel anti-CD47 antibody to the clinic that not only acts as an immune checkpoint inhibitor, but also selectively kills tumor cells (non ADCC).  The team is a highly motivated group of experienced scientists and emphasizes a collaborative approach. Arch Oncology is funded by top-quality venture capital investors and is advancing its lead mAb to the clinic currently.

7 articles with Arch Oncology, Inc